newsfilter
← Latest News
PR Newswire·

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial...